Madhura Layfield
Neuromuscular Medicine · Nashville, TNNPI 1538657358
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $582 and has fallen 83.7% since, to $95 in 2025.
Across 51 payments — averaging $30.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$292
- AstraZeneca$277
- AbbVie$242
- Averitas Pharma Inc.$200
- Johnson & Johnson$95
- Sanofi$74
- plus $382 from 10 others
What the payments were for
- Food & beverage$1,43494%
- Education$956%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 3 | $292 |
| AstraZeneca | 9 | $277 |
| AbbVie | 9 | $242 |
| Averitas Pharma Inc. | 8 | $200 |
| Johnson & Johnson | 1 | $95 |
| Sanofi | 3 | $74 |
| Alnylam Pharmaceuticals Inc. | 1 | $67 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $51 |
| CSL Behring | 3 | $51 |
| Argenx US, Inc. | 2 | $48 |
| Merz Pharmaceuticals, LLC | 2 | $47 |
| Novartis | 2 | $35 |
| EMD Serono, Inc. | 2 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Amgen | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
How this compares
Too few neuromuscular medicine providers in Tennesseeto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $62,791 |
| Emgality PenGalcanezumab-Gnlm | 28 | $23,351 |
| Mycophenolate Mofetil | 15 | $2,998 |
| Pyridostigmine Bromide | 35 | $2,944 |
| Gabapentin | 76 | $1,452 |
| Pregabalin | 45 | $745 |
| Propranolol Hcl | 17 | $663 |
| Prednisone | 55 | $495 |
| Duloxetine Hcl | 15 | $258 |
| Pantoprazole Sodium | 11 | $36 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in Nashville
- Amanda PeltierNashville$235K
- Peter DonofrioNashville$47K
- Lindsay MalatestaNashville$24K
- Stephen LayfieldNashville$2K
- John SturgisNashville$1K
- Christopher LeeNashville$379
- Lauren HerreraNashville$69
- Joshua AlpersChattanooga$623K
- Daniel Guillen MendozaMemphis$65K
- Elena CaronMemphis$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.